Given the immune-therapeutic potentials of CCL2 blockade against breast and prostate cancer [15,16], the CCL2-CCR2 target based approach may prove beneficial in reducing HIV/HCV co-morbidities. The gene discussed is CCL2; the disease is prostate carcinoma.